Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

DOP057: Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn’s disease (BELCRO)ECCO '16 Amsterdam

Year: 2016

Authors:

L. Wauters*¹, F. Smets², E. De Greef³, I. Hoffman⁴, P. Bontems⁵, S. Van Biervliet⁶, I. Paquot⁷, P. Alliet⁸, W. Arts⁹, M. De Vos¹⁰, P. Bossuyt¹¹, J.-F. Rahier¹², O. Dewit¹³, T. Moreels¹³, D. Franchimont¹⁴, V. Muls¹⁴, F. Fontaine¹⁵, E. Louis¹⁵, J.-C. Coche¹⁶, B. Hauser³, H. Peeters¹⁷, E. Van de Vijver¹⁸, F. Baert¹⁹, S. Vermeire¹, G. Veereman³

¹UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium, ²UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium, ³UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium, ⁴UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium, ⁵HUDERF, Paediatric Gastroenterology, Brussels, Belgium, ⁶UZ Gent, Paediatric Gastroenterology, Ghent, Belgium, ⁷CHC Liège, Paediatric Gastroenterology, Liège, Belgium, ⁸Jessa ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium, ⁹ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, ¹⁰UZ Gent, Gastroenterology, Ghent, Belgium, ¹¹Imelda ziekenhuis, Gastroenterology, Bonheiden, Belgium, ¹²UCL Mont Godinne, Gastroenterology, Mont Godinne, Belgium, ¹³UCL St Luc, Gastroenterology, Brussels, Belgium, ¹⁴ULB Erasme, Gastroenterology, Brussels, Belgium, ¹⁵CHU Liège, Gastroenterology, Liège, Belgium, ¹⁶St Pierre, Gastroenterology, Ottignies, Belgium, ¹⁷ST Lucas, Gastroenterology, Ghent, Belgium, ¹⁸UZ Antwerpen, Paediatric Gastroenterology, Antwerp, Belgium, ¹⁹Heilig Hart Ziekenhuis, Gastroenterology, Roeselaere, Belgium

DOP058: Long-term avoidance of steroids associated with exclusive enteral nutrition as induction therapy in paediatric Crohn’s disease does not increase surgery, hospitalisations or biologics use: results of a propensity score-matched cohort analysisECCO '16 Amsterdam

Year: 2016

Authors:

S. Basseri¹, J. Connors², A. Grant², B. MacIntyre², N. Giffin¹, G. Mahdi², A. Noble², M. Rashid², A. R. Otley², J. Van Limbergen*²

¹Dalhousie University, Halifax, Canada, ²IWK Health Centre, Halifax, Canada

DOP059: Efficacy of exclusive enteral nutrition in adult active Crohn’s disease with complications or failure of medical treatmentECCO '16 Amsterdam

Year: 2016

Authors:

Q. Yang, X. Gao*, M. Zhi, H. Chen, N. Ding, S. Hu, J. Guo, P. Hu

The Sixth Affiliated Hosptial, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China

DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared with ADA exposureECCO '16 Amsterdam

Year: 2016

Authors:

S. Kanis*¹, A. de Lima¹, C. van der Ent², C. van der Woude¹

¹Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, ²Erasmus Medical Centre, Rotterdam, Netherlands

DOP061: Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

S. Kanis*, A. de Lima, C. van der Woude

Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands

DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

L. de Ridder¹, M. Joosse*², D. Turner³, D. Wilson⁴, S. Koletzko⁵, J. Martin-de-Carpi⁶, U. Fagerberg⁷, C. Spray⁸, M. Sladek⁹, R. Shaoul¹⁰, E. Roma-Giannikou¹¹, J. Bronsky¹², D. Serban¹³, S. Cucchiara¹⁴, G. Veres¹⁵, F. Ruemmele¹⁶, I. Hojsak¹⁷, K. Kolho¹⁸, I. Davies¹⁹, M. Aloi²⁰, P. Lionetti²¹, G. Veereman-Wauters²², C. Braegger²³, E. Trindade²⁴, A. V. Wewer²⁵, A. Hauer²⁶, A. Levine²⁷

¹Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ²Erasmus MC, Laboratory of Paediatrics, division Gastroenterology and Nutrition, Rotterdam, Netherlands, ³Shaare Zedek Medical Centre in Jerusalem, Department of Paediatric Gastroenterology, Jerusalem, Israel, ⁴University of Edinburgh, Department of Paediatric Gastroenterology, Child Life and Health, Edinburgh, United Kingdom, ⁵University of Munich Medical Centre, Dr. v. Hauner Children’s Hospital, Department of Paediatric Gastroenterology, Munich, Germany, ⁶Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Paediatrica, Hospital Sant Joan de Déu, Department of Paediatric Gastroenterology, Barcelona, Spain, ⁷Centre for Clinical Research, Västmanland Hospital, Västerås, Department of Paediatric Gastroenterology, Stockholm, Sweden, ⁸Bristol Royal Hospital for Children, Department of Paediatric Gastroenterology, Bristol, United Kingdom, ⁹Polish-American Children’s Hospital, Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, ¹⁰Bnai Zion Medical Centre, Paediatric Day Care Unit, Department of Paediatrics, Haifa, Israel, ¹¹Athens University, First Department of Paediatrics, Athens, Greece, ¹²Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Paediatric Gastroenterology, Prague, Czech Republic, ¹³“Iuliu Hatieganu” University of Medicine and Pharmacy, Second Paediatric Clinic, Children’s Emergency Hospital, Department of Paediatric Gastroenterology, Cluj-Napoca, Romania, ¹⁴”La Sapienza” University, Department of Paediatric Gastroenterology, Rome, Italy, ¹⁵Semmelweis University, Department of Paediatric Gastroenterology, Budapest, Hungary, ¹⁶Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, ¹⁷Referral Centre for Paediatric Gastroenterology, Children’s Hospital Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Croatia, ¹⁸Children’s Hospital, University Central Hospital and University of Helsinki, Department of Paediatric Gastroenterology, Helsinki, Finland, ¹⁹University Hospital of Wales, Department of Paediatric Gastroenterology, Cardiff, United Kingdom, ²⁰Sapienza University of Rome, Department of Paediatric Gastroenterology, Rome, Italy, ²¹Meyer Children’s Hospital, Department of Paediatric Gastroenterology, Florence, Italy, ²²University Hospital Brussels, UZBrussels, Department of Paediatric Gastroenterology and Nutrition, Brussels, Belgium, ²³Children’s Research Centre, University Children’s Hospital, Department of Paediatric Gastroenterology and Nutrition, Zürich, Switzerland, ²⁴Hospital São João, Paediatric Gastroenterology Unit, Porto, Portugal, ²⁵University Hospital Hvidovre, Department of Paediatrics, Hvidovre, Denmark, ²⁶Medical University of Graz, Paediatric Gastroenterology, Graz, Austria, ²⁷The Wolfson Medical Centre, Tel-Aviv University, Department of Paediatric Gastroenterology, Tel-Aviv, Israel

DOP063: Measurement of endoscopic severity in a Crohn’s disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohn’s Disease Activity Index (PCDAI)ECCO '16 Amsterdam

Year: 2016

Authors:

N. Carman*¹, P. Church¹, H. Huynh², D. Mack³, K. Jacobson⁴, A. Otley⁵, J. De Bruyn⁶, W. El-Matery⁷, C. Deslandres⁸, M. Carroll², E. Wine², E. Benchimol³, J. Van Limbergen⁵, A. Griffiths¹, T. Walters¹

¹The Hospital for Sick Children, Toronto, Canada, ²University of Alberta, Edmonton, Canada, ³Children’s Hospital of Eastern Ontario, Ottawa, Canada, ⁴British Columbia Children’s Hospital, Vancouver, Canada, ⁵IWK Health Centre, Halifax, Canada, ⁶Alberta Children’s Hospital, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Sainte-Justine University Hospital Centre, Montreal, Canada

DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabECCO '16 Amsterdam

Year: 2016

Authors:

B. r*¹, M. Yavzori¹, O. Picard¹, E. Fudim¹, U. Kopylov¹, E. Del Tedesco², S. Paul², Y. Chowers³, R. Eliakim¹, S. Ben-Horin¹, X. Roblin²

¹Sheba Medical Centre & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, ²CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, ³Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel

DOP065: Less anti-infliximab antibody formation in paediatric Crohn’s patients on concomitant immunomodulatorsECCO '16 Amsterdam

Year: 2016

Authors:

H. Kansen¹, P. van Rheenen², R. Houwen¹, W. Tjon A Ten³, G. Damen⁴, A. Kindermann⁵, J. Escher⁶, V. Wolters*¹

¹University Medical Centre-Wilhelmina Children’s Hospital, Department of Paediatric Gastroenterology, Utrecht, Netherlands, ²University of Groningen, University Medical Centre Groningen, Department of Paediatric Gastroenterology, Groningen, Netherlands, ³Maxima Medical Centre, Department of Paediatric Gastroenterology, Veldhoven, Netherlands, ⁴Radboud University Medical Centre-Amalia Children’s Hospital, Department of Paediatric Gastroenterology, Nijmegen, Netherlands, ⁵Emma Children´s Hospital, Academic Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, ⁶, Erasmus Medical Centre-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands

DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

A. Strik*¹, G. van den Brink¹, C. Ponsioen¹, R. Mathot², M. Löwenberg¹, G. D’Haens¹

¹Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Centre (AMC), Hospital Pharmacy, Amsterdam, Netherlands

DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centreECCO '16 Amsterdam

Year: 2016

Authors:

J. Digby-Bell*¹, B. Warner¹, E. Johnston¹, N. Unsworth², Z. Arkir², J. Sanderson¹, P. Irving¹

¹Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, ²Guy’s and St Thomas’ NHS Foundation Trust, Reference Chemistry, Biomedical Sciences, Viapath, London, United Kingdom

DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBDECCO '16 Amsterdam

Year: 2016

Authors:

J. F. Brandse*¹, D. R. Mould², Y. K. Ashruf¹, O. Smeekes¹, S. Kuin¹, A. Strik¹, G.R. van den Brink¹, G. R. D’Haens¹

¹Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, ²Projections Research Inc, Projections Research Inc, Phoenixville, Pennsylvania, United States

DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustmentECCO '16 Amsterdam

Year: 2016

Authors:

P. Harrow*¹, C. Skinner¹, T. Hoque¹, A. Ibarra¹, J. Lindsay^{1, 2}

¹Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom, ²Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom

DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1ECCO '16 Amsterdam

Year: 2016

Authors:

X. Roblin*¹, M.T. Osterman², S. Glover³, U. Navaneethan⁴, M. A. Popa⁵, T. Wyant⁶, A. James⁷, K. Lasch⁵, M. Rosario⁶

¹CHU de Saint-Etienne, Saint-Etienne, France, ²Hospital of the University of Pennsylvania and the Presbyterian Medical Centre of Philadelphia, Philadelphia, Pennsylvania, United States, ³Southeastern Centre for Inflammatory Bowel Diseases/Affiliate Faculty Biomedical Engineering, University of Florida, Gastroenterology, Hepatology, and Nutrition, Gainesville, Florida, United States, ⁴Centre for Interventional Endoscopy, Florida Hospital, Orlando, Florida, United States, ⁵Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States, ⁶Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, United States, ⁷Takeda Development Centre Europe Ltd, London, United Kingdom

DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studiesECCO '16 Amsterdam

Year: 2016

Authors:

A. Mukherjee¹, S. Tsuchiwata², C. Deng³, C. Vong⁴, R. Xie³, S.W. Martin⁴, D. Yu⁵, D. Woodworth⁵, W. Niezychowski⁵, C. Su*⁵

¹Pfizer Inc, Groton, United States, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer Inc, Shanghai, China, ⁴Pfizer Inc, Cambridge, United States, ⁵Pfizer Inc, Collegeville, Pennsylvania, United States

DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomesECCO '16 Amsterdam

Year: 2016

Authors:

R. Battat¹, U. Kopylov*², T. Bessissow¹, A. Bitton¹, A. Cohen³, M. Martel¹, E. G. Seidman⁴, W. Afif⁴

¹McGill University Health Centre, Gastroenterology, Montreal, Canada, ²Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, ³Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, ⁴McGill University, Division of Gastroenterology, Montreal Quebec, Canada

DOP073: Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experienceU. Nosegbe*¹, J. A. Scott¹, R. O. Butcher^{1, 2}, A. M. Abbasi¹, R. C. Prudham¹, R. George¹, J. Limdi^{1, 2}ECCO '16 Amsterdam

Year: 2016

Authors:

¹The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ²University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Background: The UK Bowel Cancer Screening programme (BCSP) was launched in 2006 in England and following an age-extension, now screens individuals aged 60–74 years with a faecal occult blood test (FOBt) followed by screening colonoscopy if FOBt positive. We reported at ECCO 2012 the world’s first experience of incidental diagnosis of IBD through screening and now present an experience of incidental IBD over 7-years at our centre.

DOP074: Incidence and prediction of fistula formation in EnglandECCO '16 Amsterdam

Year: 2016

Authors:

K. Sahnan*¹, A. Askari¹, S. Adegbola*¹, P. Tozer¹, R. Phillips¹, A. Hart², O. Faiz¹

¹St Mark’s Hospital, Colorectal Surgery, London, United Kingdom, ²St Mark’s Hospital, IBD/Physiology, London, United Kingdom

DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panelECCO '16 Amsterdam

Year: 2016

Authors:

C. Siegel¹, C. Whitman², B. Spiegel², B. Feagan³, B. Sands⁴, E. Loftus⁵, R. Panaccione⁶, G. D’Haens⁷, C. Bernstein⁸, R. Gearry⁹, S. Ng¹⁰, G. Mantzaris¹¹, B. Sartor¹², M. Silverberg¹³, R. Riddell¹³, I. Koutroubakis¹⁴, C. O’Morain¹⁵, P. Lakatos¹⁶, D. McGovern², J. Halfvarson¹⁷, W. Reinisch¹⁸, G. Rogler¹⁹, W. Kruis²⁰, C. Tysk¹⁷, S. Schreiber²¹, S. Danese²², W. Sandborn²³, A. Griffiths²⁴, B. Moum²⁵, C. Gasche²⁶, F. Pallone²⁷, S. Travis²⁸, J. Panes²⁹, J.-F. Colombel⁴, S. Hanauer³⁰, L. Peyrin-Biroulet*³¹

¹Geisel School of Medicine at Dartmouth, Inflammatory Bowel Disease Centre, Lebanon, New Hampshire, United States, ²Cedars-Sinai Medical Centre, Los Angeles, California, United States, ³Roberts Clinical Trials, London, Ontario, Canada, ⁴Icahn School of Medicine at Mount Sinai, New York, New York, United States, ⁵Mayo Clinic, Rochester, Minnesota, United States, ⁶University of Calgary, Calgary, Canada, ⁷Academic Medical Centre, Amsterdam, Netherlands, ⁸University of Manitoba, Winnipeg, Canada, ⁹University of Otago, Christchurch, New Zealand, ¹⁰Chinese University of Hong Kong, Hong Kong, Hong Kong, ¹¹Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece, ¹²University of North Carolina, Chapel Hill, North Carolina, United States, ¹³Mount Sinai Hospital, Toronto, Canada, ¹⁴University Hospital Heraklion, Crete, Greece, ¹⁵Charlemont Clinic, Dublin, Ireland, ¹⁶Semmelweis University, Budapest, Hungary, ¹⁷Örebro University, Örebro, Sweden, ¹⁸McMaster University Medical Centre, Department of Gastroenterology, Hamilton, Canada, ¹⁹University Hospital Zürich, Clinic for Hepatology and Gastroenterology, Zürich, Switzerland, ²⁰University of Cologne, Clinic for Internal Medicine, Koln, Germany, ²¹Universitätsklinikum Schleswig-Holstein Kiel, Clinic for Internal Medicine, Kiel, Germany, ²²Humanitas University, Milan, Italy, ²³University of California San Diego, San Diego, California, United States, ²⁴Hospital for Sick Children, Toronto, Canada, ²⁵Oslo University, Oslo, Norway, ²⁶Medical University and General Hospital Vienna, Vienna, Austria, ²⁷University Rome, Rome, Italy, ²⁸Oxford University Hospital, Oxford, United Kingdom, ²⁹Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰Northwestern Feinberg School of Medicine, Chicago, Illinois, United States, ³¹CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France

DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.ECCO '16 Amsterdam

Year: 2016

Authors:

M. Halling¹, T. Knudsen², J. Kjeldsen¹, J. Nielsen³, L. Koch Hansen*⁴

¹Odense University Hospital, Department of Gastroenterology, Odense, Denmark, ²Esbjerg Hospital, Dept. of Gastroenterology and Hepatology, Esbjerg, Denmark, ³Odense University Hospital, Department of Clinical Epidemiology, Odense, Denmark, ⁴Vejle Hospital, Dept. of Gastroenterology and Hepatology, Vejle, Denmark